Zambon launches Xadago first in Germany, next in Switzerland
This article was originally published in Scrip
Executive Summary
Zambon has launched Xadago (safinamide), an add-on therapy for treating idiopathic Parkinson's disease in its first market, Germany. It is the first new chemical entity to be approved for Parkinson's in 10 years.
You may also be interested in...
Breath Therapeutics Snapped Up Post Series A By Specialty Company Zambon
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.